REFERENCES
- Nichols J, Snyder R W. Topical non-steroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol 1998; 9: 40–44
- Schalnus R. Topical non-steroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003; 217: 89–98
- Miller S B. Prostaglandins in health and disease: An overview. Semin Arthritis Rheum 2006; 36: 37–49
- Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282: 11613–11617
- Bito L Z. A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond: The Proctor lecture. Invest Ophthalmol Vis Sci 2001; 42: 1126–1133
- Sharif N A, Kelly C R, Crider J Y, Williams G W, Xu S X. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther 2003; 19: 501–515
- Alm A. Prostaglandin derivates as ocular hypotensive agents. Prog Retin Eye Res. 1998; 17: 291–312
- Resul B, Stjernschantz J, Selen G, Bito L. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol 1997; 41(Suppl 2)S47–52
- Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003; 217: 89–98
- Sponsel W E, Paris G, Trigo Y, Pena M, Weber A, Sanford K, McKinnon S. Latanoprost and brimonidine: Therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Am J Ophthalmol. 2002; 133: 11–18
- Costagliola C, Parmeggiani F, Antinozzi P P, Caccavale A, Cotticelli L, Sebastiani A. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp Eye Res 2005; 81: 610–615
- Costagliola C, Parmeggiani F, Caccavale A, Sebastiani A. Nimesulide oral administration increases the intraocular pressure-lowering effect of latanoprost in patients with primary open-angle glaucoma. Am J Ophthalmol 2006; 141: 379–381
- Chiba T, Kashiwagi K, Chiba N, Tsukahara S. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open-angle glaucoma or ocular hypertension. Br J Ophthalmol 2006; 90: 314–317
- Kashiwagi K, Tsukahara S. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost. Br J Ophthalmol 2003; 87: 297–301
- Buckley M M, Brogden R N. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990; 39: 86–109
- Ling T L, Combs D L. Ocular bioavailability and tissue distribution of [14C] ketorolac tromethamine in rabbits. J Pharm Sci 1987; 76: 289–294
- Abran D, Hardy P, Varma D R, Chemtob S. Mechanisms of the biphasic effects of peroxides on the retinal vasculature of newborn and adult pigs. Exp Eye Res 1995; 61: 285–292
- Li D Y, Varma D R, Chemtob S. Up-regulation of brain PGE2 and PGF2 alpha receptors and receptor-coupled second messengers by cyclooxygenase inhibition in newborn pigs. J Pharmacol Exp Ther. 1995; 272: 15–19
- Hardy P, Bhattacharya M, Abran D, Peri K G, Asselin P, Varma D R, Chemtob S, Bhatthacharya M. Increases in retinovascular prostaglandin receptor functions by cyclooxygenase-1 and-2 inhibition. Invest Ophthalmol Vis Sci. 1998; 39: 1888–1898
- Husain S, Kaddour-Djebbar I, Abdel-Latif A A. Alterations in arachidonic acid release and phospholipase C-beta(1) expression in glaucomatous human ciliary muscle cells. Invest Ophthalmol Vis Sci. 2002; 43: 1127–1134
- Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol. 2006; 50: 153–157
- Hedman K, Larsson L I. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002; 47(Suppl 1)S77–89
- Kitnarong N, Zhao Y, Netland P A, Kent A R. Efficacy of latanoprost and timolol maleate in black and white patients. Adv Ther. 2004; 21: 203–213
- Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002; 47(Suppl 1)S6–12
- Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 1998; 67: 179–191